-

Mammoth Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Virtual presentation to take place at 1:30 pm PT on Tuesday, Jan 11, 2022

BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Mammoth’s co-founder and CEO, Trevor Martin, will present a corporate overview virtually on January 11, 2022 at 1:30 p.m. PT (4:30 p.m. ET).

About Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and Casɸ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC.

Contacts

Mohana Ray
Email: Mammoth.PR@hdmz.com
Phone: 312-506-5210

Mammoth Biosciences


Release Summary
Mammoth Biosciences announces presentation at the 40th annual J.P. Morgan Healthcare Conference
Release Versions

Contacts

Mohana Ray
Email: Mammoth.PR@hdmz.com
Phone: 312-506-5210

Social Media Profiles
More News From Mammoth Biosciences

Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors

BRISBANE, Calif.--(BUSINESS WIRE)--MB-111 utilizes the ultracompact CasPhi gene editing system to permanently disrupt expression of the APOC3 gene in the liver....

Mammoth Biosciences to Present Preclinical Data on In Vivo Gene Editing of Skeletal Muscle in Non-Human Primates with an Ultracompact CRISPR System at ASGCT 2025

BRISBANE, Calif.--(BUSINESS WIRE)--Oral presentation will showcase latest results with NanoCas, Mammoth Biosciences' first efficient ultracompact extrahepatic gene editor....

Mammoth Biosciences Announces New Results on NanoCas – the First Efficient Ultracompact Extrahepatic Gene Editor

BRISBANE, Calif.--(BUSINESS WIRE)--NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues....
Back to Newsroom